News | Heart Failure | December 22, 2017

ACC Issues New Guidance to Optimize Heart Failure Treatment

Document addresses ten issues regarding heart failure with reduced ejection fraction

ACC Issues New Guidance to Optimize Heart Failure Treatment

December 22, 2017 — To help streamline treatment of patients with heart failure and ensure the best possible patient outcomes, the American College of Cardiology published an expert consensus decision pathway for the optimization of treatment for patients with heart failure with reduced ejection fraction.

“Heart failure care has become increasingly complex with multiple medications that are evidence-based, several choices of devices and an array of process of care interventions,” said Clyde W. Yancy, M.D., MSc, MACC, chair of the writing committee. “A practical approach is needed to optimize care and improve outcomes.”

This document complements the 2017 ACC/AHA/HFSA Focused Update of the 2013 ACC/AHA Guideline for the Management of Heart Failure by addressing new medical therapies, prevention and comorbidities relevant to heart failure with reduced ejection fraction for which data are available. Despite new guideline statements, information voids exist, and a practical, consensus approach is needed for areas that have incomplete evidence. The writing committee identified and addressed ten pivotal issues that remain unresolved in the guidelines:

  1. How to initiate, add or switch therapy to new evidence-based guideline-directed treatments for heart failure with reduced ejection fraction.
  2. How to achieve optimal therapy given multiple drugs for heart failure including augmented clinical assessment that may trigger additional changes in guideline-directed therapy (e.g., imaging data, biomarkers and filling pressures).
  3. When to refer to a heart failure specialist.
  4. How to address challenges of care coordination.
  5. How to improve adherence.
  6. What is needed in specific patient cohorts: African Americans, the frail and older adults.
  7. How to manage your patients’ cost of care for heart failure.
  8. How to manage the increasing complexity of heart failure.
  9. How to manage common comorbidities.
  10. How to integrate palliative care and transition to hospice care.

“There has been a challenge with implementation of guidelines across the board,” Yancy said. “This document is a major step toward deploying aspects of implementation science as a means to improve adherence to evidence-based guideline-directed therapy.”

Each member of the writing committee—representative of all stakeholders—facilitated a separate survey with their own constituency to make certain that all needs were acknowledged and addressed, if possible. This treatment document is among the first of its kind to be open to public comment during peer review. Those public comments were given the same considerations in the revisions of this document as formal peer review. According to the writing committee, this public-comments process may be a new way of developing documents, in the hope that it will allow consensus to follow much more quickly than before.

The 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction will be published online in the Journal of the American College of Cardiology.

For more information: www.acc.org

 

Related Heart Failure Content

First Transcatheter Implant for Diastolic Heart Failure Successful

Surgery Could Reduce Frailty in Adults With Heart Failure

FDA Approves Pacemaker to Treat Central Sleep Apnea

Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure

VIDEO: Predicting Right Ventricular Failure Using 2-D, 3-D and Strain Echo

Medtronic HeartWare HVAD System Approved for Destination Therapy

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Overlay Init